When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Chronic lymphocytic leukemia - Wikipedia

   en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia

   904,000 (2015) [6] Deaths. 60,700 (2015) [7] Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). [2][8] Early on, there are typically no symptoms. [2] Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason ...

3. Acalabrutinib - Wikipedia

   en.wikipedia.org/wiki/Acalabrutinib

   Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia /small lymphocytic Lymphoma (CLL/SLL). [7] It may be used both in relapsed as well as in treatment-naive settings. [8]

4. Lymphoid leukemia - Wikipedia

   en.wikipedia.org/wiki/Lymphoid_leukemia

   NK cell leukemia. Aggressive NK-cell leukemia (ANKL) is a lymphoid leukemia that is a deficiency NK cells. Not very much is known about this disease due to its rarity, but it is highly aggressive. A majority of patients with NK cell leukemia die within a year of diagnosis, and for ANKL in particular, half of patients die within two months.

5. Ofatumumab - Wikipedia

   en.wikipedia.org/wiki/Ofatumumab

   Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. [13] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. [9][11] Under the brand name Arzerra, it is approved for the treatment of ...

6. Response evaluation criteria in solid tumors - Wikipedia

   en.wikipedia.org/wiki/Response_Evaluation...

   Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. The criteria were published in February 2000 by an international collaboration including the European Organisation for Research ...

7. Alemtuzumab - Wikipedia

   en.wikipedia.org/wiki/Alemtuzumab

   Alemtuzumab. Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein.